Brickell Biotech, Inc. (BBI)
| Market Cap | 8.92M |
| Revenue (ttm) | 4.64M |
| Net Income (ttm) | -29.88M |
| Shares Out | 2.65M |
| EPS (ttm) | -0.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Jul 5, 2022 |
| Volume | 91,848 |
| Open | 3.34 |
| Previous Close | 3.27 |
| Day's Range | 3.21 - 3.42 |
| 52-Week Range | 2.88 - 37.35 |
| Beta | 0.08 |
| Analysts | Buy |
| Price Target | 49.72 (+1,379.8%) |
| Earnings Date | Aug 11, 2022 |
About BBI
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treat... [Read more...]
Financial Performance
In 2021, BBI's revenue was $404,000, a decrease of -77.83% compared to the previous year's $1.82 million. Losses were -$39.47 million, 88.8% more than in 2020.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for BBI stock is "Buy." The 12-month stock price forecast is 49.72, which is an increase of 1,379.76% from the latest price.
News
Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month
Will Brickell (BBI) Report Negative Earnings Next Week? What You Should Know
Brickell (BBI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022
BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative ...
Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement
BOULDER, Colo., July 20, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative ...
Brickell Biotech to Participate at William Blair Biotech Focus Conference 2022
BOULDER, Colo., July 06, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by devel...
Brickell Biotech Announces 1-For-45 Reverse Stock Split
Common stock will begin trading on a split-adjusted basis on July 5, 2022 Common stock will begin trading on a split-adjusted basis on July 5, 2022
Brickell Biotech (BBI) Stock Gains 50% Ahead of Meeting to Prevent Delisting
Delistings are commonplace in this bear market, however investors in Brickell Biotech and BBI stock are cheering some news today. The post Brickell Biotech (BBI) Stock Gains 50% Ahead of Meeting to Prev...
Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02
– BBI-02 is a potential first-in-class, oral DYRK1A inhibitor with strong preclinical validation and broad potential to treat debilitating autoimmune and inflammatory diseases –
Brickell (BBI) Reports Q1 Loss, Lags Revenue Estimates
Brickell (BBI) delivered earnings and revenue surprises of -33.33% and 52.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Brickell Biotech Reports First Quarter 2022 Financial Results and Provides Corporate Update
Completed sale of sofpironium bromide to Botanix Pharmaceuticals for up to $9 million in upfront and potential near-term regulatory milestone payments, $168 million in potential future regulatory and sa...
Brickell Biotech to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12, 2022
BOULDER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by develo...
Brickell Biotech Shares Surge After Offloading Late-Stage Asset To Australia-Based Firm
Brickell Biotech Inc (NASDAQ: BBI) agreed to sell sofpironium bromide rights to Australia-based Botanix Pharmaceuticals Limited. Brickell will receive upfront and potential near-term regulatory mileston...
Brickell Biotech Announces Adjournment of Annual Meeting of Stockholders
Meeting adjourned to May 17, 2022 at 10 a.m. MT
Brickell Biotech Announces Sale of Sofpironium Bromide to Botanix Pharmaceuticals
Deal includes up to $9 million in upfront and potential near-term regulatory milestone payments, $168 million in potential future regulatory and sales milestone payments, plus tiered earn out payments o...
Has Brickell Biotech (BBI) Outpaced Other Medical Stocks This Year?
Here is how Brickell (BBI) and Eli Lilly (LLY) have performed compared to their sector so far this year.
Brickell (BBI) Reports Q4 Loss, Misses Revenue Estimates
Brickell (BBI) delivered earnings and revenue surprises of 33.33% and 49.52%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Brickell Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Broadened strategic focus and expanded pipeline in immunology and inflammation following acquisition of rights to BBI-02, a potential first-in-class oral DYRK1A inhibitor, a portfolio of novel STING inh...
Brickell Biotech Selected for a Late-Breaking Oral Presentation of US Phase 3 Pivotal Cardigan I and Cardigan II Stud...
BOULDER, Colo., March 10, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by deve...
Brickell Biotech to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Corporate Update on Marc...
BOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by deve...
Brickell Biotech, Carna Biosciences Ink Licensing Pact For STING inhibitors
Brickell Biotech Inc BBI has entered into an exclusive agreement with Carna Biosciences Inc to develop and commercialize Carna's portfolio of oral Stimulator Interferon Genes (STING) antagonists. Thous...
Brickell Biotech Acquires Exclusive Global Rights to Portfolio of Novel STING Inhibitors Targeting Autoimmune and Inf...
Lead STING inhibitor candidate, BBI-10, demonstrated dose-dependent cytokine reduction in nonclinical in vitro and in vivo studies providing strong proof-of-mechanism
Brickell (BBI) Reports Q3 Loss, Misses Revenue Estimates
Brickell (BBI) delivered earnings and revenue surprises of -45.45% and -56.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Brickell Biotech Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Announced positive topline results from the Phase 3 pivotal clinical studies of sofpironium bromide gel, 15% in primary axillary hyperhidrosis patients; plan to submit a New Drug Application (NDA) to th...
Brickell Biotech to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9, 2021
BOULDER, Colo., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative ...
Brickell Biotech Prices Public Offering of Common Stock
BOULDER, Colo., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Nasdaq: BBI) (“Brickell”), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative ...